January 2, 2018 / 1:19 PM / in 9 minutes BRIEF-Syros Announces Clinical Supply Agreement With Janssen To Evaluate SY-1425 Reuters Staff 1 Min Read 
Jan 2 (Reuters) - Syros Pharmaceuticals Inc: 
* SYROS ANNOUNCES CLINICAL SUPPLY AGREEMENT WITH JANSSEN TO EVALUATE SY-1425, ITS FIRST-IN-CLASS SELECTIVE RARΑ AGONIST, IN COMBINATION WITH DARATUMUMAB IN GENOMICALLY DEFINED AML AND MDS PATIENTS 
* SYROS PHARMACEUTICALS - JANSSEN TO SUPPLY DARATUMUMAB FOR COMBINATION DOSING COHORT IN SYROS’ ONGOING PHASE 2 CLINICAL TRIAL OF SY-1425 
* SYROS PHARMACEUTICALS - JANSSEN TO RECEIVE ACCESS TO DATA FROM COHORT EVALUATING SAFETY & EFFICACY OF SY-1425 IN COMBINATION WITH DARATUMUMAB FOR RESEARCH AND DEVELOPMENT 
* SYROS PHARMACEUTICALS - ‍EXPECTS TO BEGIN ENROLLING PATIENTS IN COMBINATION COHORT WITH DARATUMUMAB IN EARLY 2018​ Source text for Eikon: Further company coverage: